Compare CHPT & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHPT | ANIK |
|---|---|---|
| Founded | 2007 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 198.9M |
| IPO Year | 2019 | 1996 |
| Metric | CHPT | ANIK |
|---|---|---|
| Price | $5.54 | $14.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 1 |
| Target Price | $9.25 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 745.8K | 57.4K |
| Earning Date | 06-03-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | $112,819,000.00 |
| Revenue This Year | $4.18 | $5.98 |
| Revenue Next Year | $16.63 | $7.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.58 | $7.90 |
| 52 Week High | $12.62 | $16.24 |
| Indicator | CHPT | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 57.13 |
| Support Level | $4.44 | $13.91 |
| Resistance Level | $7.00 | $15.93 |
| Average True Range (ATR) | 0.68 | 0.50 |
| MACD | -0.26 | 0.05 |
| Stochastic Oscillator | 12.31 | 95.80 |
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.